Tofacitinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 5 mg
Reference Brands:
Category:
Osteoporosis
Tablet contains the active constituent tofacitinib. It is used to treat Rheumatoid arthritis, Psoriatic arthritis, ulcerative colitis, polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis. Rheumatoid arthritis is a form of arthritis that causes pain, swelling, stiffness, and loss of function in the joints. Psoriatic arthritis is a form of arthritis that affects some people having psoriasis – a condition in which itchy, scaly red patches appear on the scalp and skin. Juvenile psoriatic arthritis is psoriatic arthritis affecting children.
TOFACITINIB is available in Tablets
and strengths such as 5 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, TOFACITINIB is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
TOFACITINIB can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ulcerative colitis is a disease in which inflammation and ulcers are developed in the digestive tract, primarily in the large intestine and rectum. Polyarticular juvenile idiopathic arthritis is childhood arthritis that causes swelling of joints and pain. This medication is not advisable for lactose intolerant patients as this medicine contains lactose.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing